As of Mar 27
| +0.64 / +1.91%|
The 33 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 38.91, with a high estimate of 49.78 and a low estimate of 29.20. The median estimate represents a +13.82% increase from the last price of 34.18.
The current consensus among 33 polled investment analysts is to Hold stock in Novo Nordisk. This rating has held steady since March, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.